Translate page

English English
en Englishbg Bulgarianzh-CN Chinese (Simplified)hr Croatiancs Czechda Danishnl Dutchfi Finnishfr Frenchde Germanel Greekiw Hebrewhi Hindiid Indonesianit Italianja Japaneseko Koreanmk Macedonianpl Polishpt Portuguesero Romanianru Russiansr Serbiansk Slovaksl Slovenianes Spanishsv Swedishth Thaitr Turkishvi Vietnamese

Susan Branford - the importance of Molecular Monitoring in CML

The importance of Molecular Monitoring in CML

Susan Branford, University of Adelaide, Australia

Please click on the image below to watch the webcast, and a window will open. You can then also click on the slides to jump to certain sections of the presentation. Please share your feedback below, and view the other Virtual Education Program modules.

 

webcast-button
vep branford molecmonitoring

 

Issues covered

  • Measurement of BCR-ABL transcript levels to assess residual disease
  • Recommended monitoring for CML
  • The significance of achieving a major molecular response

Has this been helpful? Please provide your comments here:

Facteur de variabilité de la réponse au ITK</li>
              <li>Les trois grand mécanismes de résistance</li>
              <li>La réponse au traitement</li>
              <li>Autres inhibiteurs de tyrosine kinase: le Nilotinib et le Dasatinib

John Goldman: CML Treatment with imatinib

John Goldman: CML Treatment with imatinib

Please click on the image below to watch the webcast, and a window will open. You can then also click on the slides to jump to certain sections of the presentation. We appreciate your feedback: Please rate the video with the radio buttons above, share your comments using comments box below, or share your ideas in our Discussion Forum. View the other Virtual Education Program modules.

 

webcast-button
iv-goldman

Issues covered in this presentation:

  • Biology and mechanisms of CML
  • Mechanism of action of imatinib
  • Results of the IRIS study
  • Adverse effects of imatinib
  • Methods to detect residual disease
  • Imatinib in children and in pregnancy
  

 

Has this been helpful? Please provide your comments here:

Timothy Hughes - Optimising response and managing resistance to treatment

Please click on the image below to watch the webcast, and a window will open. You can then also click on the slides to jump to certain sections of the presentation. We appreciate your feedback: Please rate the video with the radio buttons above, share your comments using comments box below, or share your ideas in our Discussion Forum. View the other Virtual Education Program modules.

 

webcast-button
iv-hughes

 

Issues covered in this presentation:

  • Definition of optimal response to imatinib
  • Suboptimal response
  • Considerations for managing suboptimal response, case study
  • Adherence and molecular response
  • Role of mutations, criteria for mutation screening on first line therapy
  • Dose related toxicities with TKI’s; concomitant medications

 

Has this been helpful? Please provide your comments here:

Michele Baccarani - European Leukemia Network (ELN) recommendations

Michele Baccarani - European Leukemia Network (ELN) recommendations

Please click on the image to start the presentation. While watching the presentation, you can also click on each of the small slides to jump to the sections. We appreciate your feedback: Please rate the video with the radio buttons above, share your comments using comments box below, or share your ideas in our Discussion Forum. View the other Virtual Education Program modules.

 

webcast-button
iv-baccarani

Issues covered in this presentation:

  • Predicting response to imatinib
  • Depth of response, does it matter?
  • Primary and secondary failure to imatinib
  • How to monitor response
  • Treatment recommendations

 

Has this been helpful? Please provide your comments here:

Jorge Cortes - Treatment of patients after imatinib first line therapy

Jorge Cortes - Treatment of patients after imatinib first line therapy

Please click on the video to start the presentation. While watching the presentation, you can also click on each of the small slides to jump to the sections. We appreciate your feedback: Please rate the video with the radio buttons above, share your comments using comments box below, or share your ideas in our Discussion Forum. View the other Virtual Education Program modules.

 

webcast-button
iv-cortes

 

Issues covered in this presentation:

  • Survival post imatinib
  • Treatment with 2nd generation TKIs (2nd line, 1st line)
  • Optimal time to switch therapy
  • Strategies to prevent imatinib failure
  • Role of interferon and transplantation
  • Presentation of new agents under investigation

 

Has this been helpful? Please provide your comments here:

  1. Interview with Tim Hughes